[500.com Limited Announces Financial Results For the Fourth Quarter and Full Year of 2015 SHENZHEN, China, February 24, 2016—500.com Limited (NYSE: WBAI) (“500.com” or the “Company”), a leading online sports lottery service provider in China, today reported its unaudited financial results for the fourth quarter and full year of 2015. Temporary Suspension of Online Lottery Sales Since March 2015, all] []
[500.com Limited Announces Financial Results For the Fourth Quarter and Full Year of 2015 SHENZHEN, China, February 24, 2016—500.com Limited (NYSE: WBAI) (“500.com” or the “Company”), a leading online sports lottery service provider in China, today reported its unaudited financial results for the fourth quarter and full year of 2015. Temporary Suspension of Online Lottery Sales Since March 2015, all] []
[China Yuchai International Announces 2015 Unaudited Fourth Quarter and Full Year Financial Results SINGAPORE, Singapore February 24, 2016 China Yuchai International Limited Financial Highlights for the Fourth Quarter of 2015 Net revenue declined to RMB 2.9 billion (US$ 450.7 million) compared with RMB 3.9 billion in the fourth quarter of 2014; Gross profit was RMB 692.1] [CHINA YUCHAI INTERNATIONAL LIMITED UNAUDITED CONSOLIDATED INCOME STATEMENTS For the quarters ended December 31, 2015 and 2014 (RMB and US$ amounts expressed in thousands, except per share data) December 31, 2015 December 31, 2014 RMB000 US$000 RMB000 US$000 Revenue 2,926,451 450,667 3,920,895 603,809 Cost of goods sold (2,234,311 ) (344,079 ) (2,950,802 ) (454,417 ) Gross profit 692,140 106,588 970,093] [TABLE OF CONTENTS 99.1 Press release dated February 24, 2016 China Yuchai International Announces 2015 Unaudited Fourth Quarter and Full Year Financial Results 99.2 Unaudited Financial Statements for Year Ended December 31, 2015 CHINA YUCHAI INTERNATIONAL LIMITED Weng Ming Hoh President and Director 6-K 1 d147650d6k.htm FORM 6-K]
[China Yuchai International Announces 2015 Unaudited Fourth Quarter and Full Year Financial Results SINGAPORE, Singapore February 24, 2016 China Yuchai International Limited Financial Highlights for the Fourth Quarter of 2015 Net revenue declined to RMB 2.9 billion (US$ 450.7 million) compared with RMB 3.9 billion in the fourth quarter of 2014; Gross profit was RMB 692.1] [CHINA YUCHAI INTERNATIONAL LIMITED UNAUDITED CONSOLIDATED INCOME STATEMENTS For the quarters ended December 31, 2015 and 2014 (RMB and US$ amounts expressed in thousands, except per share data) December 31, 2015 December 31, 2014 RMB000 US$000 RMB000 US$000 Revenue 2,926,451 450,667 3,920,895 603,809 Cost of goods sold (2,234,311 ) (344,079 ) (2,950,802 ) (454,417 ) Gross profit 692,140 106,588 970,093] [TABLE OF CONTENTS 99.1 Press release dated February 24, 2016 China Yuchai International Announces 2015 Unaudited Fourth Quarter and Full Year Financial Results 99.2 Unaudited Financial Statements for Year Ended December 31, 2015 CHINA YUCHAI INTERNATIONAL LIMITED Weng Ming Hoh President and Director 6-K 1 d147650d6k.htm FORM 6-K]
[Biostar Pharmaceuticals Regains Compliance with NASDAQ $1.00 Minimum Bid Price XIANYANG, China, February 24, 2016 -- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“Biostar”), a PRC-based developer, manufacturer and marketer of pharmaceutical and health supplement products in China, today announced that on February 22, 2016, NASDAQ notified the Company that it had regained compliance with continued listing Rule 5550(a)(2), which requires a] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): February 24, 2016 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]
[Biostar Pharmaceuticals Regains Compliance with NASDAQ $1.00 Minimum Bid Price XIANYANG, China, February 24, 2016 -- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“Biostar”), a PRC-based developer, manufacturer and marketer of pharmaceutical and health supplement products in China, today announced that on February 22, 2016, NASDAQ notified the Company that it had regained compliance with continued listing Rule 5550(a)(2), which requires a] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): February 24, 2016 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]
